COVID-19 Use Causes Tocilizumab Shortage

被引：4
|
作者：
Leslie, Mitch
机构：
来源：
CANCER DISCOVERY | 2021年 / 11卷 / 12期
关键词：
D O I：
10.1158/2159-8290.CD-NB2021-0386
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Based on mounting evidence that tocilizumab improves survival in critically ill patients with COVID-19, the FDA granted it an emergency use authorization for COVID-19 treatment in June. Two months later, the agency added tocilizumab to its list of drug shortages, where it remains despite a slowly increasing supply. ©2021 American Association for Cancer Research.
引用
收藏
页码：2950 / 2954
页数：5
相关论文
共 50 条
  • [21] TOCILIZUMAB USE IN SEVERE COVID-19: A SINGLE CENTER EXPERIENCE
    Poon, Joseph
    Ho, Kam Sing
    Herrera, Yasmin
    Jean, Raymonde
    [J]. CHEST, 2020, 158 (04) : 687A - 687A
  • [22] ACTIVE TB AFTER THE USE OF TOCILIZUMAB FOR COVID-19 INFECTION
    Noh, Sungryong
    Dronavalli, Goutham
    [J]. CHEST, 2021, 160 (04) : 289A - 289A
  • [23] Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
    Cortegiani, A.
    Ippolito, M.
    Greco, M.
    Granone, V.
    Protti, A.
    Gregoretti, C.
    Giarratano, A.
    Einav, S.
    Cecconi, M.
    [J]. PULMONOLOGY, 2021, 27 (01): : 52 - 66
  • [24] The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers
    Rubio-Rivas, Manuel
    Mora-Lujan, Jose M.
    Montero, Abelardo
    Aguilar Garcia, Josefa Andrea
    Mendez Bailon, Manuel
    Fernandez Cruz, Ana
    Oriol, Isabel
    Teigell-Munoz, Francisco-Javier
    Dendariena Borque, Beatriz
    De la Pena Fernandez, Andres
    Fernandez Gonzalez, Raquel
    Gil Sanchez, Ricardo
    Fernandez Fernandez, Javier
    Catalan, Marta
    Cortes-Rodriguez, Begona
    Mella Perez, Carmen
    Montero Rivas, Lorena
    Suarez Fuentetaja, Rebeca
    Ternero Vega, Jara Eloisa
    Ena, Javier
    Martin-Urda Diez-Canseco, Anabel
    Perez Garcia, Cristina
    Varona, Jose F.
    Manuel Casas-Rojo, Jose
    Millan Nunez-Cortes, Jesus
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2022, 37 (01) : 168 - 175
  • [25] Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes
    Navas, Natalia
    Hermosilla, Jesus
    Torrente-Lopez, Anabel
    Hernandez-Jimenez, Jose
    Cabeza, Jose
    Perez-Robles, Raquel
    Salmeron-Garcia, Antonio
    [J]. JOURNAL OF PHARMACEUTICAL ANALYSIS, 2020, 10 (06) : 532 - 545
  • [26] Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes
    Natalia Navas
    Jesús Hermosilla
    Anabel Torrente-López
    José Hernández-Jiménez
    Jose Cabeza
    Raquel Pérez-Robles
    Antonio Salmerón-García
    [J]. Journal of Pharmaceutical Analysis, 2020, 10 (06) : 532 - 545
  • [27] Tocilizumab for severe COVID-19 pneumonia
    Piano, Salvatore
    Vettor, Roberto
    Angeli, Paolo
    [J]. LANCET RHEUMATOLOGY, 2020, 2 (11): : E659 - E660
  • [28] Thromboinflammation response to tocilizumab in COVID-19
    Gergi, Mansour
    Cushman, Mary
    Littenberg, Benjamin
    Budd, Ralph C.
    [J]. RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2020, 4 (08) : 1262 - 1268
  • [29] Response to "Tocilizumab therapy and COVID-19"
    Bhargava, Pallavi
    [J]. JOURNAL OF OSTEOPATHIC MEDICINE, 2021, 121 (11): : 867 - 868
  • [30] Audio Interview: Tocilizumab and Covid-19
    Rubin, Eric J.
    Baden, Lindsey R.
    Morrissey, Stephen
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (17): : E114 - E114
12345